Consistently with these findings in patients, indicating a tumor-suppressive role of EZH2 in MDS, mice lacking Ezh2 have enhanced initiation and progression of Runx1-mutant MDS [30]. This evidence concerns the gene EZH2 and myelodysplastic syndrome.